rhil 21 r d systems 8879 il cf (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems rhil 21 r d systems 8879 il cf
Rhil 21 R D Systems 8879 Il Cf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil-+21/Recombinant+Human+IL-21+Protein%2C+CF/us12378526-348-174-175
Average 93 stars, based on 16 article reviews

rhil 21 r d systems 8879 il cf - by Bioz Stars, 2026-09

93/100 stars

Images

Expressing:

Article Title: Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial-Mesenchymal Transition and Correlates with Progression of the Disease.
Article Snippet: .. To investigate whether interleukin (IL)-6, IL-21 and IL-23 modulate hepcidin expression, HCEC-1ct cells (2.5 × 105) were stimulated with recombinant human IL-6 (Peprotech, London, UK), IL-21 and IL-23 (R&D Systems, Minneapolis, MN, USA) (all used at 20 ng/mL). ..

Article Title: Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
Article Snippet: Cryopreserved patient samples were thawed and labelled with 1 μM Cell Trace Violet (ThermoFisher) as described previously6. .. Cells were cultured on mouse embryonic fibroblast cells stably expressing the human CD40 ligand in the presence of rhIL-21 (25 ng/ml, R&D systems). .. After 7 days, cells were stained with CD5-APC (clone BL1a, Beckman Coulter) and CD19-BV510 (clone SJ25CI, BD Biosciences), and analyzed by FACSCytoflex (BD) before assessing proliferation using FlowJo software.

Recombinant:

Article Title: Cyclooxygenase-1 Regulates the Development of Follicular Th Cells via Prostaglandin E 2 .
Article Snippet: .. Purified naive CD4+ T cells were sorted from C57BL/6 mice and then were stimulated with anti-CD3 (0.5 mg/ml; eBioscience) and antiCD28 (1 mg/ml; eBioscience) on plates for 48 h in DMEM medium in the presence of recombinant human IL-2 (100 U/ml) and cytokine mixture as follows: for TFH cell–like: 20 ng/ml IL-6, IL-21 (R&D Systems), 10 mg/ml anti–IFN-g (Bio X Cell), and 10 mg/ml anti–IL-4 (R&D Systems); for TH1: anti–IL-4 10 mg/ml and IL-12 10 ng/ml; for TH2: 10 mg/ml anti–IL12 (C17.8; eBioscience),10 ng/ml IL-4 (R&D Systems), and 10 mg/ml anti–IFN-g; for TH17: 20 ng/ml IL-6 (R&D Systems), 1 ng/ml TGF-b (R&D Systems),10 mg/ml anti–IL-4, and 10 mg/ml anti–IFN-g; and for regulatory T (Treg) cell: 5 mg/ml anti–IL-4, 10 mg/ml anti–IFN-g, 5 ng/ml TGF-b (R&D Systems), and 200 U/ml IL-2. ..

Purification:

Transfection:

Article Title: Combining computational target prioritization and a B cell maturation assay for target evaluation studies in systemic lupus erythematosus.
Article Snippet: Background and Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving production of autoantibodies by B cells.. This study aimed at identifying novel drug targets using a computational algorithm to select targets and thereafter validate the top ranked 11 targets by siRNA knockdown in a primary B cell maturation assay.. Experimental Approach: The top 1 % genes (~150 genes) from SLE genome-wide association studies were ranked by Priority index (Pi), a computational tool integrating genomic and network information to prioritize diseaserelevant genes.

Suspension:

Concentration Assay:

Article Title: Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay.
Article Snippet: A final volume of 200 l/well were seeded in 96 well round-bottom plates (Sarstedt). .. Probes and compounds diluted to 1M (1:10000) or 0,1M (1:100000) in DMSO, or only DMSO (0,01%, v/v) were added and plates were incubated 30 min at 37° C. Soluble rhCD40L (final concentration 500 ng/ml, R&D Systems), rhIL-21 (final concentration 50 ng/ml, R&D Systems), rhIL-10 (final concentration 200 ng/ml, R&D Systems), rhIL-4 (final concentration 200 ng/ml, R&D Systems) and CpG ODN2006 (final concentration 1 g/ml, Miltenyi Biotec) were added, and plates were further incubated at 37° C for six days. ..

Article Title: Composition for culturing natural killer cells and method for preparing natural killer cells by using same
Article Snippet: .. TABLE 1 Basal culture medium 1 Components Manufacturer Cat. # Dose Final concentration CTS TM Immune Thermo A2596102 0.5 ml 5% Cell SR (Serum replacement) GLUTAMAX GIBCO A12860-01 0.5 ml 1X 100X rhIL-15 R&D systems 247-ILB/CF adding 66.7 IU immediately before use rhiL-21 R&D systems 8879-IL/CF adding 0.341 IU immediately before use anti-CD2/ Miltenyi Biotec 130-094-483 CD335 Beads OKT3 Biolegend 317326 10 ng/mL AIM-V medium GIBCO 0870112-DK to 50 ml TABLE 2 Basal culture medium 2 Components Manufacturer Cat. # Dose Final concentration Human AB serum Sigma H4522 2.5 ml 5% GLUTAMAX GIBCO A12860-01 0.5 ml 1X 100X rhIL-15 R&D systems 247-ILB/CF adding 66.7 IU immediately before use rhIL-21 R&D systems 8879-IL/CF adding 0.341 IU immediately before use anti-CD2/ Miltenyi Biotec 130-094-483 CD335 Beads OKT3 Biolegend 317326 10 ng/mL AIM-V medium GIBCO 0870112-DK to 50 ml TABLE 3 Basal culture medium 3 Components Manufacturer Cat. # Dose Final concentration Human AB serum Sigma H4522 2.5 ml 5% GLUTAMAX GIBCO A12860-01 0.5 ml 1X 100X rhIL-15 R&D systems 247-ILB/CF adding 66.7 IU immediately before use rhIL-21 R&D systems 8879-IL/CF adding 0.341 IU immediately before use anti-CD2/ Miltenyi Biotec 130-094-483 CD335 Beads OKT3 Biolegend 317326 10 ng/mL X-VIVO TM 15 Lonza 04-418Q to 50 ml Medium TABLE 4 Basal culture medium 4 Components Manufacturer Cat. # Dose Final concentration Human AB serum Sigma H4522 2.5 ml 5% NK MACS Miltenyi Biotec 130-113-102 500 1% supplement anti-CD2/ Miltenyi Biotec 130-094-483 CD335 beads OKT3 Biolegend 317326 10 ng/mL NK MACS 130-112-968 to 50 ml medium TABLE 5 Adding material Classification Components Manufacturer Dose Final concentration Adding GI-101 GI-Innovation adding 1.6 nM/50 nM condition 1 immediately before use Adding GI-101WT GI-Cell adding 1.6 nM/50 nM condition 2 immediately before use Adding CD80-Fc + GI-Cell adding CD80-Fc (1.6 nM) + condition 3 Fc-IL2WT immediately Fc-IL2WT (1.6 nM)/ before use CD80-Fc (50 nM) + Fc-IL2WT (50 nM) Adding CD80-Fc + GI-Cell adding CD80-Fc (1.6 nM) + condition 4 Fc-IL2v2 immediately Fc-IL2v2 (1.6 nM)/ before use CD80-Fc (50 nM) + Fc-IL2v2 (50 nM) ..

Cell Culture:

Article Title: Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering.
Article Snippet: Primary human NK cell culture and nucleofection Cryopreserved human peripheral blood CD56+ cells were purchased from StemCell Technologies (StemCell No. 70037) and expanded using the Cloudz Human NK Cell Expansion kit (R&D Systems No. CLD004) according to the manufacturer’s protocol. .. Upon thaw, NK cells were seeded in T25 flasks with Cloudz anti-CD2- and anti-NKp46-coated microspheres and cultured in ExCellerate human NK cell expansion media (R&D Systems No. CCM032) supplemented with 10% FBS and varying concentrations of rhIL-2, rhIL-12, rhIL-18, and rhIL-21 (R&D Systems Nos. ..

Stable Transfection:

Enzyme-linked Immunosorbent Assay:

Article Title: Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults.
Article Snippet: Background.. The recent success achieved with the use of B celldepleting agents in some patients with minimal change nephrotic syndrome (MCNS) suggests an unexpected role for B lymphocytes in the pathogenesis of this immune-mediated glomerular disease.. Nevertheless, no extensive B-cell phenotyping analysis has ever been performed in untreated adult patients soon after MCNS diagnosis.

Review